These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
243 related articles for article (PubMed ID: 10900559)
1. Serum cholesterol in patients with obsessive compulsive disorder during treatment with behavior therapy and SSRI or placebo. Peter H; Tabrizian S; Hand I Int J Psychiatry Med; 2000; 30(1):27-39. PubMed ID: 10900559 [TBL] [Abstract][Full Text] [Related]
2. Serum cholesterol level comparison: control subjects, anxiety disorder patients, and obsessive-compulsive disorder patients. Peter H; Hand I; Hohagen F; Koenig A; Mindermann O; Oeder F; Wittich M Can J Psychiatry; 2002 Aug; 47(6):557-61. PubMed ID: 12211884 [TBL] [Abstract][Full Text] [Related]
3. Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder. A double-blind, placebo-controlled study in patients with and without tics. McDougle CJ; Goodman WK; Leckman JF; Lee NC; Heninger GR; Price LH Arch Gen Psychiatry; 1994 Apr; 51(4):302-8. PubMed ID: 8161290 [TBL] [Abstract][Full Text] [Related]
4. Combined fluvoxamine and extended-release methylphenidate improved treatment response compared to fluvoxamine alone in patients with treatment-refractory obsessive-compulsive disorder: A randomized double-blind, placebo-controlled study. Zheng H; Jia F; Han H; Wang S; Guo G; Quan D; Li G; Huang H Eur Neuropsychopharmacol; 2019 Mar; 29(3):397-404. PubMed ID: 30595354 [TBL] [Abstract][Full Text] [Related]
5. A randomized controlled trial of Japanese patients with obsessive-compulsive disorder--effectiveness of behavior therapy and fluvoxamine. Nakatani E; Nakagawa A; Nakao T; Yoshizato C; Nabeyama M; Kudo A; Isomura K; Kato N; Yoshioka K; Kawamoto M Psychother Psychosom; 2005; 74(5):269-76. PubMed ID: 16088264 [TBL] [Abstract][Full Text] [Related]
6. Cognitive-behavioral therapy as an adjunct to serotonin reuptake inhibitors in obsessive-compulsive disorder: an open trial. Simpson HB; Gorfinkle KS; Liebowitz MR J Clin Psychiatry; 1999 Sep; 60(9):584-90. PubMed ID: 10520976 [TBL] [Abstract][Full Text] [Related]
7. [Efficacy and tolerability of escitalopram in anxiety disorders: a review]. Pelissolo A Encephale; 2008 Sep; 34(4):400-8. PubMed ID: 18922243 [TBL] [Abstract][Full Text] [Related]
8. Use of factor-analyzed symptom dimensions to predict outcome with serotonin reuptake inhibitors and placebo in the treatment of obsessive-compulsive disorder. Mataix-Cols D; Rauch SL; Manzo PA; Jenike MA; Baer L Am J Psychiatry; 1999 Sep; 156(9):1409-16. PubMed ID: 10484953 [TBL] [Abstract][Full Text] [Related]
10. Fluvoxamine. An updated review of its use in the management of adults with anxiety disorders. Figgitt DP; McClellan KJ Drugs; 2000 Oct; 60(4):925-54. PubMed ID: 11085201 [TBL] [Abstract][Full Text] [Related]
11. Double-blind study of dextroamphetamine versus caffeine augmentation for treatment-resistant obsessive-compulsive disorder. Koran LM; Aboujaoude E; Gamel NN J Clin Psychiatry; 2009 Nov; 70(11):1530-5. PubMed ID: 19573497 [TBL] [Abstract][Full Text] [Related]
12. Long-term follow-up and predictors of clinical outcome in obsessive-compulsive patients treated with serotonin reuptake inhibitors and behavioral therapy. Alonso P; Menchon JM; Pifarre J; Mataix-Cols D; Torres L; Salgado P; Vallejo J J Clin Psychiatry; 2001 Jul; 62(7):535-40. PubMed ID: 11488364 [TBL] [Abstract][Full Text] [Related]
14. A double-blind, placebo-controlled study of the efficacy and safety of controlled-release fluvoxamine in patients with obsessive-compulsive disorder. Hollander E; Koran LM; Goodman WK; Greist JH; Ninan PT; Yang H; Li D; Barbato LM J Clin Psychiatry; 2003 Jun; 64(6):640-7. PubMed ID: 12823077 [TBL] [Abstract][Full Text] [Related]
15. Cognitive-behavioral therapy vs risperidone for augmenting serotonin reuptake inhibitors in obsessive-compulsive disorder: a randomized clinical trial. Simpson HB; Foa EB; Liebowitz MR; Huppert JD; Cahill S; Maher MJ; McLean CP; Bender J; Marcus SM; Williams MT; Weaver J; Vermes D; Van Meter PE; Rodriguez CI; Powers M; Pinto A; Imms P; Hahn CG; Campeas R JAMA Psychiatry; 2013 Nov; 70(11):1190-9. PubMed ID: 24026523 [TBL] [Abstract][Full Text] [Related]
16. Transcutaneous electrical acupoint stimulation as an adjunct therapy for obsessive-compulsive disorder: A randomized controlled study. Feng B; Zhang ZJ; Zhu RM; Yuan GZ; Luo LY; McAlonan GM; Xu FZ; Chen J; Liu LY; Lv YY; Wong HK; Zhang Y; Zhu LX J Psychiatr Res; 2016 Sep; 80():30-37. PubMed ID: 27281260 [TBL] [Abstract][Full Text] [Related]